Board of Directors
William Z. Levine – Chairman
William Z. Levine, DDS, is the director and founder of the Jerusalem Perio Center, the largest and foremost private healthcare facility specializing in the treatment of oral diseases and implantology in Israel. A Diplomate of the American Board of Periodontology with seven registered patents, Dr. Levine is a practicing periodontist with over 20 years of clinical experience, and a frequently featured speaker at international forums on periodontal disease and implantology. Dr. Levine is an active board member of several hospitals and healthcare centers in Israel. He received his DDS and Certificate of Periodontology at Columbia University, New York.
Jack V. Talley is a pharmaceutical management professional with more than 30 years of experience in the industry. He has taken three companies successfully public. He has been responsible for more than 20 equity issuances in both the private and public sectors raising in aggregate in excess of $100 million. Two of the three companies he has taken public have been successfully sold, the third is still independent. He has been responsible for numerous business development transactions and has secured product approvals in both Europe and the United States for a wide variety of investigational drugs. Most recently he was the President, CEO and a member of the Board of Directors for Alissa Pharma, LLC a privately held company focused on antibody directed isotopes for various forms of cancer. Previously he was the CEO, President and a Director of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from the position of President, Chief Executive Officer and a Director at EpiCept Corporation which he also took public. Prior to EpiCept, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, Inc., a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process. Prior to joining Consensus, Mr. Talley led Penwest Ltd.’s efforts in its IPO spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo. Mr. Talley led the alliance between Penwest and Endo. Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs when the company was merged with Sanofi, he launched various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.
Elliot F. Hahn, Ph.D. currently serves as an Executive Director of Izun Pharmaceuticals Corporation. Dr. Hahn is also the Executive Chairman of Accu-Break Pharmaceuticals, Inc., a privately held company. He co-founded Andrx Corporation and was Chairman Emeritus and a Director of Andrx until its acquisition by Watson Pharmaceuticals, Inc. in November 2006 for $1.9 billion. He was President of Andrx from 1993 until 2003, served as Chairman of the Board from 2002-03 and as interim CEO from 2001-02. From June 1990 until February 1993, Dr. Hahn was Vice President for Scientific Affairs of IVAX, where he was involved in the evaluation and licensing of product opportunities and was responsible for maintaining IVAX’s intellectual property. Prior to that, he was Vice President of Research at the pharmaceutical subsidiary of IVAX. Before joining IVAX, Dr. Hahn was an associate professor at The Rockefeller University, an assistant professor at Albert Einstein College of Medicine, and a member of the Institute for Steroid Research at Montefiore Hospital, all in New York City. He received a Ph.D. in Organic Chemistry from Cornell University. Dr. Hahn received a B.S. with Honors in Chemistry from the City College of New York. He has authored or co-authored over sixty peer-reviewed scientific publications.
Mr. Schafer is the Managing Partner of O.S.S. Capital Management LP, a private investment partnership which he co-founded in 2001. A well-respected Wall Street professional, he has been a longtime participant in the Barron’s Roundtable of top money managers. Previously, Mr. Schafer was a Member of Cumberland Associates and, prior to that, was a General Partner at Steinhardt Partners, which he joined in 1970 as an analyst. He earned a BA, Magna Cum Laude, at Harvard College in 1961 and an MBA at Harvard Business School in 1964. Mr. Schafer serves on the Board of Trustees of New York-Presbyterian Hospital. He is President of the Schafer Family Foundation, which supports the arts and social service organizations. He serves on the Executive Committee of the University Club and is on the Board of the New York Philharmonic, which he serves as chairman of the nominating committee. Oscar Schafer is married to Didi Fenton-Schafer, who serves on the Board of the Central Park Conservancy and the Second Stage Theater. He has two daughters and two step-daughters. The couple is a generous special events donor and was an underwriter of the Orchestra’s 9/11 Tenth Anniversary Concert. From the summer seasons of 2007 through 2012, Didi and Oscar Schafer presented the New York Philharmonic’s Concert in the Parks, and will continue to do so during the upcoming season as well.
Hersh Cooper graduated from Melbourne University in Australia with Bachelor of Laws (Hons) and Bachelor of Commerce degrees in 1973. He practiced as an Attorney until 1997, specializing in Taxation and Mergers and Acquisitions. He served as director and/or Chairman of several listed public companies. Since moving to Israel in 1997, he has been active in the property development sector as well as acting as legal Counsel for several Australian companies operating in Israel. In addition to serving on the Board of Izun, he holds a Board position at FIBI Holdings Ltd., the publicly listed holding company of the First International Bank of Israel and several charities.
Sharon Kochan is Executive Vice President and GM, International for Perrigo Company plc, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC), generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients with annual sales approaching $5 Billion and Market cap of over $24 Billion. After over a decade in various roles of increasing responsibilities, Sharon Kochan was promoted in 2007 to an Executive Vice President role with responsibility to grow and lead the Rx Pharma segment of Perrigo, which had just less than $100M in annual sales and single digit Operating Income at that time. Through strategic guidance and operational leadership, the Perrigo Rx Pharma segment annual sales consistently expanded to cross the $0.75B mark with Operating Income of $300M in FY13 and continues to grow and flourish after Sharon was assigned to lead the International segment of Perrigo in 2013, a segment that is now enjoying significant growth and turnaround. Sharon holds a BSc. degree in Industrial Engineering, cum laude, from Tel-Aviv University, and MSc. degree in Management Science – Operations Research from Columbia University in NYC.
Michael G. Jesselson
Michael G. Jesselson serves as the President and Chief Executive Officer at Jesselson Capital since 1994. Mr. Jesselson has been a Lead Independent Director at XPO Logistics, Inc. since March 21, 2016. Mr. Jesselson has been an Independent Director of XPO Logistics Inc., since September 2, 2011. He has been the Lead Independent Director at American Eagle Outfitters, Inc. since 2012 and has been its Independent Director since November 1997. He serves as a Director of U*tique, Inc., CereSpir Incorporated, C-III Capital Partners LLC and Qualcomm Connected Experiences, Inc. He has numerous non-profit affiliations, including the Chairman of American Friends of Bar-Ilan University, Co-Chairman of Shaare Zedek Medical Center Board of Directors in Jerusalem, Trustee of Yeshiva University, Board Member of SAR Academy, Board Member of UJA-Federation of New York, Board Member of the Center for Jewish History, Trustee of the American Jewish Historical Society, Board Member of Hebrew University of Jerusalem, Board Member of the National Museum of American Jewish History and Board Member of the Leo Baeck Institute.